Healthcare Private Placement and M&A Transactions Review Week Ending December 11 2022

Entactbio: The company raised $81 million in Series A venture funding in a deal led by Qiming Venture Partners and venBio on December 6, 2022, putting the company’s pre-money valuation at $32.8 million. Arkin Bio-Ventures, Abingworth, Brandon Capital and 5 other investors also participated in the round. The company is a developer of a biotechnology research business designed to enhance the function of beneficial proteins.

Dantari: The company raised $47 million of Series A venture funding in a deal led by Westlake Village BioPartners on December 8, 2022. Alexandria Venture Investments, Corner Ventures, and California Institute of Technology Endowment also participated in the round. The company is an operator of a biotechnology usiness intended to create breakthrough medicines for the treatment of cancer and other serious diseases.

ABK Biomedical: The company raised $30 million of Series C venture funding in a deal co-led by Santé Ventures and an undisclosed MedTech strategic investor on December 6, 2022. Eight Roads, F-Prime Capital, and other undisclosed investors also participated in the round. The company is a developer of a microspheres product designed to improve the treatment of hypervascular tumors.

Rejoni: The company raised $25 million of Series B venture funding in a deal led by Catalyst Health Ventures on December 7, 2022, putting the company’s pre-money valuation at $79.3 million. Ascension Ventures, Delos Capital, AMED Ventures, Iyengar Capital Partners and Sparta Group also participated in the round. The company is a developer of surgical instruments designed to offer products that improve the outcomes of minimally invasive and other gynecological surgical procedures.

Kiyatec: The company raised $18.1 million of venture funding from undisclosed investors on December 8, 2022. The company is a developer of advanced 3D cell culture technology designed to predict patient response to therapies before the treatment begins.

Cardiosense: The company raised $15.1 million of Series A venture funding in a deal led by Broadview Ventures and Hatteras Venture Partners on December 8, 2022. OSF Ventures, UnityPoint Health Ventures, Portal Innovations, and Laerdal Million Lives Fund also participated in the round. The company is a developer of a digital biomarker platform designed to leverage multi-sensor devices and proprietary algorithms to detect early signs of disease.

Gennao: The company raised $15 million of venture funding from undisclosed investors on December 8, 2022. The company is a developer of targeted nucleic acid therapeutics intended to cure muscle diseases.

Convelo Therapeutics: The company raised $10.8 million of venture funding from undisclosed investors on December 8, 2022. The company is an operator of a biotechnology business intended to discover and develop a new class of medicines that unlock the regenerative capacity of the central nervous system.

Jellagen: The company raised GBP 8.7 million through the combination of debt and Series A venture funding in a deal led by Thai Union Group, Development Bank of Wales and Cardiff Capital Region on December 8, 2022, putting the company’s pre-money valuation at GBP 14.1 million. The company is a manufacturer of collagen products designed for application in 2D and 3D cell culture and medical devices.

ImmuneSensor Therapeutics: The company raised $10 million of Series A venture funding from undisclosed investors on December 5, 2022, putting the company’s pre-money valuation at $100 million. The company is a developer of novel medicines designed to harness innate immunity to treat cancer and autoimmune disease.

Bactobio: The company raised GBP 5.9 million of venture funding in a deal led by Bridford Group on December 5, 2022, putting the company’s pre-money valuation at GBP 43.2 million. Peder Holk Nielsen and Hugh Grant also participated in the round. The company is a biotechnology business intended to harvest valuable metabolites from biological dark matter.

Dawn: The company raised an undisclosed amount of venture funding in a deal led by Kindred Ventures on December 5, 2022. Bragiel Brothers also participated in the round. The company is a developer of cognitive-behavioral therapy (CBT) intended to help a person sleep better.

AVM Biotechnology / BioMed360 Solutions Corp: The company reached a definitive agreement to be acquired by BioMed360 Solutions Corp for an undisclosed amount on December 5, 2022. The company is a developer of a biotechnology platform designed to fight cancer, infectious disease, and autoimmune disorders.

Complion / RealTime Software Solutions: The company was acquired by RealTime Software Solutions, via its financial sponsor LLR Partners, through an LBO on December 6, 2022 for an undisclosed amount. The company is a developer of document management and workflow platform intended to serve clinical research sites, academic medical centers (AMCs), hospitals, health systems, sponsors and contract research organizations.

Neurescence / Bruker: The company was acquired by Bruker for an undisclosed amount on December 5, 2022. The company is a developer of a miniature microscope designed to simultaneously monitor the activities of neurons in multiple regions of the brain and the spinal cord of freely behaving subjects.

Zerinol / Zentiva: Zentiva, via its financial sponsor Advent International, has entered into a definitive agreement to acquire the Zerinol and Schoum Solution of Sanofi through an LBO on December 6, 2022 for an undisclosed amount. The company is a manufacturer and supplier of drugs intended to cure colds and flu.